• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Galera Therapeutics Inc. (Amendment)

    5/1/24 5:01:34 PM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRTX alert in real time by email
    SC 13G/A 1 ea0205114-13ga1schneid_gale.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 1)

     

    GALERA THERAPEUTICS INC.

     

    (Name of Issuer)

     

    COMMON STOCK

     

    (Title of Class of Securities)

     

    36338D108

     

    (CUSIP Number)

     

    April 19, 2024

     

    (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following page(s)

     

     

     

    Page 1 of 5 Pages

     

    CUSIP No. 36338D108 13G/A Page 2 of 5 Pages

     

    1.

    NAMES OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  

     

    Yair Schneid

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: 

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY  

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

    5. SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      10,823,610 Shares (1)
    6. SHARED VOTING POWER
       
      None
    7. SOLE DISPOSITIVE POWER
       
      10,823,610 Shares (1)
    8. SHARED DISPOSITIVE POWER
       
      None
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      10,823,610 Shares (1)
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
       
      [   ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
       
      19.90%
    12. TYPE OF REPORTING PERSON
       
      IN

     

    (1)Based on 54,392,170 shares outstanding as of March 28, 2024 as reported on Form 10-K for the period ended December 31, 2023 filed with the Securities and Exchange Commission on March 28, 2024.

     

     

     

    CUSIP No. 36338D108 13G/A Page 3 of 5 Pages

     

    ITEM 1(a) NAME OF ISSUER: Galera Therapeutics Inc.

     

    ITEM 1(b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

     

    45 Liberty Blvd., Suite 230, Malvern, Pennsylvania 19355

     

    ITEM 2(a) NAME OF PERSON FILING: Yair Schneid

     

    ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

    1 Wood Lane, Suffern, NY 10901

     

    ITEM 2(c) CITIZENSHIP: USA

     

    ITEM 2(d) TITLE OF CLASS OF SECURITIES: Common Shares, $0.001 par value per share

     

    ITEM 2(e) CUSIP NUMBER: 36338D108

     

    ITEM 3IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

     

    ITEM 4OWNERSHIP

     

    (a) AMOUNT BENEFICIALLY OWNED: 10,823,610 Shares (1)

     

    (b) PERCENT OF CLASS: 19.90% (1)

     

    (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

     

    (i) SOLE POWER TO VOTE OR DIRECT THE VOTE

     

    10,823,610 Shares (1)

     

    (ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

     

    0 Shares

     

    (iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    10,823,610 Shares (1)

     

    (iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    0 Shares

     

     

     

    CUSIP No. 36338D108 13G/A Page 4 of 5 Pages

     

    ITEM 5OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Not applicable

     

    ITEM 6OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable

     

    ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable

     

    ITEM 8IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

     

    Not applicable

     

    ITEM 9NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable

     

     

     

    CUSIP No. 36338D108 13G/A Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      May 1, 2024
      (Date)
       
      /s/ Yair Schneid
      (Signature)
       
      Yair Schneid
      (Name/Title)

     

     

     

     

     

    Get the next $GRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRTX

    DatePrice TargetRatingAnalyst
    8/10/2023$6.00 → $0.50Overweight → Neutral
    Piper Sandler
    12/20/2021$11.00 → $20.00Buy
    Citigroup
    12/15/2021$10.00Neutral → Buy
    HC Wainwright & Co.
    12/15/2021$15.00Neutral → Buy
    BTIG
    10/20/2021Buy → Neutral
    HC Wainwright & Co.
    10/19/2021$17.00 → $2.00Buy → Underperform
    BofA Securities
    10/19/2021Buy → Neutral
    BTIG Research
    More analyst ratings